Drug Type Trispecific T-cell engager (TriTE) |
Synonyms- |
Target |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Breast Cancer | Preclinical | US | Modex Therapeutics, Inc.Startup | 23 Feb 2022 |
HER2 Positive Breast Cancer | Preclinical | US | 23 Feb 2022 |